Vaccine expert Ruth Karron discusses the authorization of COVID-19 vaccines for those under 5 years old, and what's likely to happen with the authorization over the next few weeks
Novavax uses a combination of spike proteins and an immune stimulant to provoke an immune response against the virus that causes COVID-19. Vaccine expert William Moss discusses its strengths and weaknesses ahead of its potential emergency use authorization.
Johns Hopkins health security expert Tom Inglesby provides an update on the state of the pandemic and how vaccination, funding, and variants may affect its future
Experts say the tragic milestone, now recorded by the Coronavirus Resource Center tracker, likely occurred months ago and that higher vaccination rates could have prevented many fatalities
Researchers at Johns Hopkins had already been developing chatbots to combat vaccine misinformation when the coronavirus pandemic arrived, giving their work greater urgency
Findings differ from earlier reports of low antibody responses in children exposed to COVID-19 virus and suggest that even the youngest children may respond to vaccines if correct dose is determined
COVID-19 is inching toward endemic status in the U.S., but a clear seasonal pattern has yet to emerge. Meanwhile less than 66% of the total population has been vaccinated.
A pre-omicron study reviewed four vaccines, finding that they retain nearly all of their ability to prevent severe disease up to six months after full vaccination